Fusion is ultimately a tool which can be deployed by organisations to manage their physical assets (buildings and land). This need usually drives towards a decision to divest the organisation of a site in its entirety or, in some cases, a need to repurpose part of a site where some of the capacity needs to be retained.
Fusion consists of three key elements:
The process.
This is four stages that include:
A set of values and considerations that are to be considered and tested throughout the whole process. This is the central core of the Fusion process which runs from Scouting right through to Implementation, consistently testing everything against agreed values.
A strict data-led approach which means decisions are taken based on knowledge and data rather than hope and belief. Decisions are therefore always made on a fully informed basis.
Astra Zeneca was exiting a very large research facility set in parkland. The site consisted of a number of separate buildings including warehousing, offices, conferencing, and staff welfare and specialist science research facilities.
Novartis was exiting a modern vaccine packaging facility located in Speke Liverpool. The facility was a modern new-build consisting of temperature controlled warehouse, sterile manufacturing facilities, offices and staff welfare facilities.
Following a review of its global business pharmaceutical company Sanofi announced the intention to close its manufacturing plant at Fawdon in the north-east of England.
Sanofi had a commitment to approaching site closure in a way that treats staff fairly and recognises the company’s Corporate Social Responsibility.
Sanofi appointed SOG’s Fusion Team to consider the various options for Fawdon in the lead up to closure. SOG was selected due to its success in coordinating the sale and regeneration of a major Sanofi manufacturing site in Dagenham, east London, which led to SOG creating Londoneast-uk Business and Technical Park.
University College London were looking to relocate their trial research facility and develop a major purpose-built research building. The facility conducts experiments regarding the movement of people through specifically public transport spaces. Access to people and a thriving business hub were key necessities.
Novartis was exiting a modern vaccine packaging facility located in Speke Liverpool. The facility was a modern new-build consisting of temperature controlled warehouse, sterile manufacturing facilities, offices and staff welfare facilities.
SOG was appointed by Avecia to take charge of Facilities Management at the biotech and specialist chemical company’s global headquarters at Hexagon Tower, Blackley, in Manchester.
The 11-storey Hexagon Tower with 85,000 square feet of laboratories and 100,000 square feet of offices was originally a single business location and part of the old ICI empire.
Following the sale of a number of Avecia businesses, Hexagon Tower was transformed in 2003 into a multi-occupancy facility housing 14 separate companies and employing around 500 people.
Global pharmaceutical company Sanofi announced its manufacturing plant in Dagenham, east London, was to close in 2013.
The aim was to regenerate the site to attract new businesses and jobs to a location which had been a major source of employment for over 80 years.
Londoneast-uk now sits at the heart of a thriving location with a film studio, Europe’s largest data centre (currently under construction) and a number of other large projects including a hotel, regional offices and a pub/restaurant.
When chemicals giant ICI announced the closure of its polymers division based at The Heath in Runcorn, Cheshire, in 2000 with the loss of 1,600 jobs it was seen as the death knell for Runcorn.
Now SOG plans to further transform the site to meet the challenges of the 21st century by creating Heath Park – with a vision to turn the location into a fantastic, sustainable, futuristic environment where people can work, live and play.